A prospective surveillance for chemotherapy-induced nausea and vomiting

A prospective surveillance for chemotherapy-induced nausea and vomiting - A prospective surveillance for chemotherapy-induced nausea and vomiting

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006456

Enrollment

900

Registered

2011-10-03

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient is scheduled to receive his/her first course of highly or moderately emetogenic chemotherapy 2) Patient is planning the chemotherapy of at least two or more courses 3) Patient is able to complete study diary

Exclusion criteria

Exclusion criteria: 1) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 2) Patient is judged that it is unsuitable as a study patient by investigator (e.g. patient cannot complete study diary)

Design outcomes

Primary

Measure	Time frame
Complete Response (no emesis and no rescue therapy) in overall phase (1 to 7 days)	—

Secondary

Measure	Time frame
1) Complete Response in acute (day 1) and delayed (2 to 7 days) phase 2) Control rate of nausea/vomiting 3) dietary intake 4) Incidence of constipation 5) Degree of satisfaction to treatment of nausea and vomiting	—

Countries

Japan

Contacts

Public ContactSatoru Izumitani

Hiroshima University Hospital Department of Pharmaceutical Services

izumit@hiroshima-u.ac.jp082-257-5575

Outcome results